In ten minutes a day, You too can be ON TOP of the biopharma industry
Call John D Waddell, RPh @ +1-610-952-1871
TSM Associates are…
Creative
Experienced
Committed
BioPharma Industry News
-
Calm on Cleveland Clinic Ca ward. Beautiful sun rises over water
-
Harvard Biz Rev: Generic corp culture steeped in greed & dysf(x)
-
Point-counterpoint on mounting concerns with GLP-1 drugs
-
Puma up as GSK's Tykerb shows no threat to neratinib in MBC
-
Valeant wants Activis which wants Warner Chilcott.. & on & on
-
XBiotech takes aim at inflammation that weakens Ca patients
-
Bayer has received 3 FDA oncology approvals in last 8 mos
-
DSM-IV task force chair presses attack on DSM-V
-
Fever-reducing drugs don't speed recovery from infection
-
Global biosimilars mrkt forecasted to $2.445B in 2013
-
GSK bets on volume growth with emerging markets price cuts
-
India caps prices on 650 drugs; GSK, Sanofi hit hardest
-
It's been another IPO-intensive couple of weeks in biopharma
-
MA rep reintroduces legislation for clinical trial data transparency
-
Oramed gets FDA IND clearance to start US oral insulin trials
-
Roche & QB3 team up to launch startups in the Bay Area
-
Sanofi reports Ph 3 myelofibrosis win for JAK2 inh, SAR302503
-
Warner Chilcott buy may be Actavis' best takeover defense
-
ZS: "Geeks.. running the numbers..helping..sales..be efficient"
-
AbbVie gives Galapagos $50M for more for JAK1, GLPG0634
-
CMS has $1B in grants to "rapidly reduce" Medicare spending
-
FDA AE d'base ID's issues w/ 5-HT3's, metoprolol succinate ER's
-
FDA guidance & Sunshine regs: Divergent paths, redundancies
-
Novartis scientists make synthetic H7N7 flu vax in one week
-
Novo completes first Ph 3 for N9-GP in hemophilia B
-
Purdue & Transcept pull Intermezzo DTC & cut 90 contract reps
-
Risperdal suits keep on coming; Kentucky sues J&J
-
Scotland ignores conventional wisdom with bold steps vs hep C
-
WHO reports 1st patient-to-nurse spread of SARS-like virus
-
AHRQ: Urgent improvement needed in quality of diabetes care
-
Australian judge invalidates Merck Vioxx class action settlement
-
EMA releases ICH guideline on mfrg impurities for consultation
-
Evotec & Harvard partner to develop new antibacterials
-
Impax begins shipping auth generic of AstraZeneca's Zomig
-
Medicare spending projections are plummeting - The Atlantic
-
Novartis' Vasella exit opens door to Roche stake sale
-
OnDeck Biotech: Online connection for biotechs & contract services
-
Pharma seeks flexibility in rating Antibiotics Incentives Now Act
-
Psychs unveil long-awaited diagnostic "bible", DSM-V
-
Rib-X & Ligand start Ph 3 for delafloxacin in ABSSSI
-
Roche & Biogen file for re-hearing of GSK Arzerra appeal
-
Sanofi & French govt at odds on plans for Toulouse R&D site
-
Teva treads lightly in morning-after controversy
-
Wireless pill bottle wins Healthcare Innovation World Cup
-
EMA: Bayer's Diane 35 & generics safe for appropriate acne use
-
FDA guidance on e-health data, pooled data in Ph 4 studies
-
J&J faces criminal charges in South Korea over Tylenol mfrg
-
NEJM: Is FDA approving too many drugs starting with 'X' & 'Z'?
-
Novartis says it has no intention of buying Actavis
-
Off-label drug use to boost cognitive performance in UK
-
On a price-quality ratio, Switzerland has best healthcare
-
UCB & IBM system to translate big data @ point of epilepsy care
-
US children's mental illness costs $247B per year and is rising
-
2 regions in South & mid-Atlantic have 4x avg sepsis death rate
-
AMA's 2012 profit down by a third despite 3.2% membership rise
-
Amgen, Novartis join Atlas Venture in $265M biotech fund
-
Anaphore changes name to RuiYi & focus to biologics for China
-
BMS data suggests cocktail approach to advanced melanoma
-
Chemo, radiation & radioactive follow-up not always needed
-
Docs & ethicists dispute patient need for genome/exome info
-
Evidence "implementation gap" at small-to-mid-size biotechs
-
Fitch puts RPI on negative watch over intent to acquire Elan
-
NIH looks to reformulation, social media vs opioid abuse
-
Ranbaxy perpetuated systemic cover-up for nearly a decade
-
Stemline prices $60M public offering of common stock
-
Sweden's Recipharm looks to sell or list in Stockholm
-
Synthetic biology may hasten the development of flu vaxes
-
Tekmira's RNAi for Ebola achieves critical milestone
-
ThromboGenics: US sales of Jetrea top $10M in 2013
-
WHO's cash prizes vs patents good enough to scare pharma
-
107 drug recalls documented in 1Q13, up from 4Q12 & 1Q12
-
Alliance Boots plans to double China ops within two years
-
Ambit forced to offer a deep discount on IPO shares
-
AstraZeneca: Moxetumomab, olaparib & selumetinib go to Ph 3
-
Big pharma fears India's patent battle will inspire others
-
Brainwashed: The seductive appeal of mindless neuroscience
-
FDA loosens regs on 'smart pills' transmittig messages from GI
-
Novo CEO scolds EU officials for 'empty promises' on new drugs
-
Office for Human Research Protections wrong on risk & consent
-
Pharmas are cool with YouTube but fear Twitter
-
Pundits use of single ACA studies/data inapt vs fundamentals
-
Quest Diagnostics acquires Humana's Concentra lab biz
-
Sanofi taps Jerome Bettis for anaphylaxis campaign, Auvi-Q
-
UK Office of Fair Trading accuses GSK of pay-for-delay
-
ASCO: PD-1 & PDL-1, cell death drugs, may be the biggest news
-
Bayer buys private Steigerwald Arzneimittelwerk herbal meds
-
Cubist bid $1B for Optimer before sale process even began
-
Ex-NICE chair's appt to Intra-Cellular board raises COI fears
-
FDA approves J&J's anti-TNF, Simponi for ulcerative colitis
-
FDA warning didn't change for-profit dialysis drug use
-
Genfit's dual PPAR, GFT505 cuts remnant cholesterol CV risk
-
Myriad BRCA 1&2 case is tip of 'genomic freedom' iceberg
-
NEJM: Intense surveillance of H7N9 virus is warranted
-
New tools help patients decide when to skip chemotherapy
-
Roche exploring sale of diabetes device biz: Medtronic, J&J?
-
Roche's MPDL3280A well tolerated & effective in variety of Ca's
-
WHO: "Dramatic" life expectancy gains show no sign of slowing
-
"Very strong relationship" w/ fitness & middle-age Ca survival
-
Alliance Boots defends tax pmts; Corp tax modest part of total
-
Brazil generics mrkt expected to grow dramatically by 2020
-
FDA approves Bayer's Xofigo in adv prostate Ca w/ bone mets
-
Gilead's oral idelalisib effective in Ph 1 in recurrent CLL
-
In mass customization era, big data approach is a little odd
-
India unveils cheap alternative to GSK, Merck rotavirus vaxes
-
Kite Pharma gets $35M in Ser A for Ca immunotherapies
-
Medicare Drug Savings Act 2013: Hospitals profit from 340B
-
Poliwogg & Microryza: New crowdfunding initiatives for biotech
-
Quintiles & Merck KGaA sign 5-year exclusive R&D deal
-
Roche says CLL data for GA101 will top MabThera pre-expiry
-
Samyang licenses Cynviloq, paclitaxel to Sorrento & Igdrasol
-
Sanofi & Regeneron start recruiting Ph 3 RA trials for sarilumab
-
Sequencing cost deceleration may be slowing
-
Tokai gets $35.5M in Ser E for galeterone in prostate Ca
-
Univ of OR scientists create human stem cells through cloning
-
US Senate confirms Tavenner as Medicare/Medicaid chief
-
WHO data shows narrowing health, child mortality gap
-
WHO: Viet Nam vax deaths with J&J Quinvaxem coincidental
-
Actavis rejected Mylan's $15B bid to pursue Warner Chilcott
-
Are trials to compare efficacy of biosimilars even ethical?
-
Bayer starts liver Ca Ph 3 for potential blockbuster, regorafenib
-
BMS targets heart-failure and fibrosis drugs in R&D effort
-
FDA approves Arbor's Nymalize in brain hemorrhage
-
FDA approves EGFR companion diagnostic for Roche's Tarceva
-
HHS' $1B initiative to fund innovations in federal health programs
-
Omeros closes $16.2M direct offering with 2% premium
-
Ranbaxy may resume exports after resolving criminal charges
-
Sanofi taps PatientsLikeMe.com to recruit for clinical trials
-
The weird and wonderful world of 3D printing
-
Treatment guidelines for pediatric ADHD rarely followed
-
US DOJ charges 89 defendants in 8 cities with health fraud
-
"Weight loss gut bacterium" found... ...for mice
-
100 best-selling pharmaceuticals in 1Q13 (retail & hospital)
-
43 AGs ask FDA urged to place Black Box Warning on opioids
-
AbbVie gives Alvine $70M upfront for AVL003, anti-gluten drug
-
Animal-rights & and disease activists target Merck leaders
-
Community screenings at hospitals make overtreatment worse
-
Did Elan overpay on Theravance to spurn hostile suitor?
-
Drug biz pushes back against refill reminder rule; 100M per yr
-
FujiFilm pays $10/60M for Cempra's solithromycin in Japan
-
Hambug on mfrg standards: How good is good enough?
-
Like it or not, researchers & scientists, you're in sales
-
Lipitor generics help NHS save $1.52M per day
-
OR lesson: Want to improve health care? Spend less on it
-
Pfizer recs normal dividend & special animal health dividend
-
ProPublica: Part D fails to monitor prescribers, puts pats @ risk
-
Surge in dengue fever cases prompts UK to warn travelers
-
The Street reiterates GSK as a buy on revenue growth
-
Astellas shuts down OSI, Perseid in restructuring of R&D
-
AstraZeneca, Astellas & Cubist M&A reports lift Optimer shrs
-
Biotech shrs off to best start since inception w/out approvals
-
CA SB 598 would allow substitution of lower-cost biosimilars
-
Cornell cocaine vax shows promise in monkey trial
-
FDA accepts Biogen BLA for long-lasting Eloctate in hemoph A
-
FDA approves lower doses for zolpidem sleep drugs
-
FDA moves give Purdue an edge in opioid analgesic market
-
FDA slams Endo for misuse of data in Opana ER Citizen Petition
-
FDA strategies to Prevent and respond to drug shortages
-
FDA to study of use of composite scores in DTC advertising
-
French regulator fines Sanofi $53M for generic 'smear campaign'
-
House panel is investigating resignation of top FDA official
-
Huge drug cost disparities undermine Obamacare (esp Ca)
-
Immune-boosting Ca drugs may signal paradigm shift
-
Industry confronts healthcare's changing oncology practices
-
Isis: Has RNA therapeutics & orphan drug devt frenzy died?
-
J&J unit gets priority revenue for simeprevir NDA in hep C
-
JAMA: Adult-observed ADHD reflects, validates true rate in kids
-
Lancet: Inoculating communities against vaccine scare stories
-
Merck KGaA expects to achieve 2014 guidance a year early
-
Middle East coronavirus & H7N9 could both spark global outbreaks
-
NEJM: MA PCOC sites old data to support anti industry bias
-
Novartis kickback cases, a shift toward civil vs criminal charges
-
P&T: Proposed FDA approval criteria for biosimilars
-
Pharma and CRO execs question sponsor oversight of CROs
-
Radius to post Ph 2 data for osteoporosis patch, BAO58 in Sep
-
Ranbaxy pays DOJ $500M to settle long-running mfrg scandal
-
SEC investigating Spectrum on steep drop in Fusilev sales
-
Shire's Nimbus Rare dis deal: Interesting science & financing
-
Stem cell industry approaching highly visible Ph 2 & 3 catalysts
-
Teva considering the acquisition of Adcock Ingram
-
Vivus adds two new directors to board amid pressure
-
Walgreen, CVS extend Mmulti-year pharmacy network deal
-
Actavis shares up 9.6% on news of Warner Chilcott discussions
-
Astellas, Daiichi Sankyo say new drugs will Propel growth
-
Big pharma is selling far fewer pills, but at a much higher price
-
Biohit Oyj sees promise in China for Acetium GI Ca prevention
-
Biopharma winners led by Warner Chilcott; Losers, Optimer
-
Biotech IPO's are back: Markets draw life science start-ups
-
CDER solicits comments on product devt R&D and promo issues
-
Charity & big pharma are uneasy bedfellows: Is it way forward?
-
Dyax prices $30M diect offering to develop DX-2930 in HAE
-
Elan to pay $1B for stake in Theravance respiratory royalties
-
Endo loses bid to stop non-abuse-deterrent, Opana ER generics
-
FDA patient Web site seeks engagement in decision-making
-
Fears grow as WHO says coronavirus is communicable
-
Fresenius SE eyes small and mid-sized acquisition targets
-
Goldman Sachs invests $20M in Indian medical device maker
-
GSK pursues an invention waiting to happen: 'Electroceuticals'
-
Health reform underscores need to engage patients before trials
-
High valuations transform biotechs from targets into buyers
-
Israel tells Teva to pay more taxes after 0.3% rate paid in 2011
-
It's an optimistic time for pharma's dealmakers
-
JACC: PCI deaths under-reported; Reporting leads to underuse
-
Medicines patent pool: Big pharma's toe still in the water
-
Michael J Fox back in prime-time; Parkinson's in check w/ meds
-
No doubt, wireless monitoring will be huge & transformative
-
NYC wins $70M from 44 biopharmas in Medicaid fraud suit
-
Patent expires in 2012 contributed $28.9B decline in drug spend
-
Pfizer has 2nd Levoxyl recall, tabs don't meet potency standard
-
Plan to provide NJ Sanofi facility with solar power postponed
-
Practicing psychiatrists will pay little attention to DSM-5
-
Psych's big new battleground; Does mental illness really exist?
-
PwC: Pharmaceutical & Life Sciences Deals Insights Quarterly
-
Sanofi touted as bidder for Adcock Ingram after Bidvest offer
-
Thermo Fisher sued over sale of Mexico plant drug cartel used
-
Vectura joins new biotech JV in China for respiratory therapies
-
Warburg Pincus raises $11.2B PE fund as interest rates wallow
-
Will Array become a late-stage biopharmaceutical company?
-
Abbott spin off, AbbVie's head of R&D will retire @ 55
-
Actavis could be in early talks to acquire Warner Chilcott
-
Aetna, BC & BS of MN, UnitedHealth on areas ripe for innovation
-
Amgen & Zhejiang Beta form JV to bring Vectibix to China mrkt
-
Analysts wary of Breo/Ellipta chances beyond COPD indication
-
Biogen makes $3.5M pmt to Isis for SMNRx in spinal atrophy
-
CMS overpaid $529M for Medicare anemia drugs in 2011
-
Drug firms find new way to shorten clinical trials
-
Drugmakers face more scrutiny of discordant US prices
-
Faster drug approvals a tonic for pharma industry
-
FDA approves Novartis' IL-1, Ilaris in childhood arthritis
-
FDA draft guidance clarifies compassionate use process
-
FDA OK's GSK, Theravance's Breo Ellipta in COPD; Launch, 3Q13
-
Frazier Healthcare closes in on $300M biotech VC fund
-
GSK, Merck & Gavi deal reflects growing efforts for world's poor
-
IMS: Cheaper drugs don't add up to greater use, persistence
-
In search of the silver bullet: The illusion of big data
-
Inheritable mosquito infection prevents malaria transmission
-
J&J's $2.2B DOJ settlement on hold; J&J seeks Risperdal shelter
-
Lilly ends devt of enzastaurin in lymphoma; Takes $30M charge
-
McKinsey: The coming era of 'on-demand' marketing
-
Millennium CEO retires in management shakeup at Takeda
-
NIH: Neutralizing ABs prevent infxn by majority of HIV strains
-
NIMH & DSM-5: Psych needs to focus on biological causes of dis
-
Out of the glare of the public markets, Quintiles has flourished
-
Pain Therapeutics: Pfizer reassessing Remoxy partnership
-
Rockwell set to disrupt dialysis mrkt w/ new drugs, DaVita deal
-
Shire Regenerative Med opens healtogether.com for foot ulcers
-
Shire wins Lialda patent trial against generic mfr, Watson
-
Sir Witty's GSK pays for trng of Save the Children health workers
-
Strong antigen & MHC affinity up T cells, prevent Ca relapse
-
The Atlantic: The right relationship between docs & drug cos
-
Trevena gets $430M Forest deal, $60M serC for TRV027 HF Ph2b
-
US senators appear close to finalizing drug compounding bill
-
Why we don't understand translational science; Why it matters
-
Woodcock: FDA not fully aware of compounding problem's scope
-
"Encouraging" signs for e-Therapeutics' ETS2101 in Ph 1 for oesophageal Ca
-
10 ASCO 2013 abstracts you can read right now
-
10% of congenital heart defects from spontaneous mutations
-
2012 US drug spending fell for first time in in at least 55 years
-
Actavis part 2: Warner Chilcott shares rise 16% in heavy volume
-
Agent Orange tied to aggressive prostate Ca risk
-
Air pollution may raise risk of diabetes precursor in kids
-
Amarin trouble grows with evidence against fish oil benefits
-
AmerisourceBergen completes divestiture of Andersonbrecon pkg biz
-
AstraZeneca: Assessing your asthma is key to taking control
-
Bluebird bio & PTC Therapeutics mount campaigns to go public
-
Callidus raises $4.6M in a private stock sale for ultra rare dis(s)
-
Cautious optimism healthcare spending growth has slowed
-
Chiasma fires a third of workforce despite Roche Octreolin deal
-
Children born after flu exposure may 4-fold higher bipolar risk
-
Community pharmacies now back supply chain legislation
-
Contract Pharma's 2013 Annual Outsourcing Survey
-
CytRx ends tamibarotene on Ph 2b loss; Focuses on aldoxorubicin
-
Dendreon's Provenge sales drop again as competition heats up
-
Discovery Labs prices $14.25M public offering of common stock
-
Drug companies blast WA county's pill disposal plan
-
Edarbyclor is only ARB chlorthalidone combination on the mrkt
-
Even best wt loss drug mktg plans face payer & pricing issues
-
Failure of AstraZeneca's Vimovo isn't the end for Pozen
-
FDA accepts Seagen's sBLA for Adcetris retreatment and extended duration
-
FDA draft guidance on charging for investigational drugs
-
Former breast Ca Action exec dir dies at 61 of ALS
-
France sees coronavirus case after Saudi Arabia outbreak
-
GAVI Alliance: Cost of HPV vax in developing countries is $4.50
-
Giant Eagle sues AstraZeneca & 3 generic mfrs on Nexium
-
GOP congressman won't nominate for Indep Pmt Adv Board
-
GSK, Merck reduce HPV vax prices in poorest regions
-
Halozyme rises on Ph 1 data for PEGPH20 in pancreatic Ca
-
Herbal sexual supplements often contain Viagra API
-
How to best outsource the development of biosimilars
-
India CCI probes Cipla for anti-competitive practices
-
Is Cellceutix Kevetrin's "Guardian Angel" P53 gene activation the "Holy Grail" of Ca R&D
-
J&J outlines poppy supply plans beyond Tasmania
-
Jury out in another jawbone death case for Novartis' Zometa
-
Karyopharm raises $20.5M for Ca drugs, KPT-330 & KPT-335
-
Merck rep seeks $100M in sex-discrimination suit
-
Mobile health app startups should think social for testers
-
Moody's lowers Merck's long-term debt rating
-
NEJM: Only 5-6% of US hep C pats have been successfully treated
-
Novartis considers bid for Actavis as battle heats up
-
Novartis properly warned of Zometa's risks, jury decides
-
NPS' Gattex launch off to good start with 160 Rxs for $250K drug
